(Q38541943)

4 September 2017

1 reference

title

Targeting α-synuclein as a therapeutic strategy for Parkinson's disease (English)

1 reference

4 September 2017

1 reference

1 reference

Nada B Lawand

1

1 reference

4 September 2017

Nayef E Saadé

series ordinal

2

1 reference

4 September 2017

Omar M El-Agnaf

series ordinal

3

1 reference

4 September 2017

Bared Safieh-Garabedian

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 July 2015

1 reference

Expert Opinion on Therapeutic Targets

4 September 2017

published in

1 reference

4 September 2017

volume

19

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

1351-1360

1 reference

Prodromal non-motor symptoms of Parkinson's disease.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

BAG1 is neuroprotective in in vivo and in vitro models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Pathogenic mechanisms of neurodegeneration in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

The many faces of α-synuclein: from structure and toxicity to therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Molecular interaction of α-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

The role of phosphorylation in synucleinopathies: focus on Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Biomarkers in biological fluids for dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

CSF biomarkers and clinical progression of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Cerebrospinal fluid biomarkers in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

α-Synuclein in cutaneous autonomic nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Cell-to-cell transmission of non-prion protein aggregates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

The prion hypothesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

A generic method for design of oligomer-specific antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Antibodies against alpha-synuclein reduce oligomerization in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Intrabodies as neuroprotective therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Rational design of potent domain antibody inhibitors of amyloid fibril assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Cytokines in the central nervous system: targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Neural and immune mechanisms in the pathogenesis of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Inflammatory and cell death pathways in brain and peripheral blood in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Could astrocytes be the primary target of an offending agent causing the primary degenerative diseases of the human central nervous system? A hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Glial reactions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Thymulin reverses inflammatory hyperalgesia and modulates the increased concentration of proinflammatory cytokines induced by i.c.v. endotoxin injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Exenatide and the treatment of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

21 January 2018

Physiology of microglia

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

Caspase activation precedes and leads to tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

The ubiquitin-proteasome system in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2015.1062877

10.1517/14728222.2015.1062877

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference